iRhythm (IRTC)
Healthcare
Close on Nov 6, 2026 (from our latest article): $90.22
- Market value
- $3.0Bat the Nov 6 close
- Revenue growth
- +22%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- 1%12 months to Sep 30, 2026 (10-Q)
- Net debt
- $91Mat Sep 30, 2026
- Worst fall since listing
- −84.4%Jan 20, 2021 to Aug 19, 2021; not back to that high (−64.9% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
What the filings say about the story, dilution and cash runway.
No Long View yet. Request one →
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for iRhythm, FY2014–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $22M in FY2014 to $747M in FY2025.
Free cash flow was positive in 1 of the 12 years shown; FY2025: $35M.
Margins
Operating margin was −8% in FY2025, vs −16% in FY2020.
Gross margin was 71% in FY2025, vs 73% in FY2020.
Diluted share count
The diluted share count rose 15% from FY2020 to FY2025, to 32M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $747M | 71% | −8% | −$45M | $81M | $46M | $35M |
| FY2024 | $592M | 69% | −20% | −$113M | $3M | $34M | −$31M |
| FY2023 | $493M | 67% | −25% | −$123M | −$50M | $40M | −$91M |
| FY2022 | $411M | 69% | −28% | −$116M | −$23M | $30M | −$53M |
| FY2021 | $323M | 66% | −31% | −$101M | −$38M | $28M | −$66M |
| FY2020 | $265M | 73% | −16% | −$44M | −$14M | $14M | −$27M |
| FY2019 | $215M | 76% | −26% | −$55M | −$22M | $20M | −$42M |
| FY2018 | $147M | 74% | −31% | −$50M | −$29M | $5M | −$34M |
| FY2017 | $99M | 72% | −28% | −$30M | −$15M | $4M | −$18M |
| FY2016 | $64M | 67% | −24% | −$21M | −$17M | $3M | −$19M |
| FY2015 | $36M | 59% | −60% | −$23M | −$18M | $2M | −$20M |
| FY2014 | $22M | 51% | −68% | −$16M | −$16M | $0.5M | −$16M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 32M | $584M | $650M | $88M | — | $0 |
| FY2024 | 31M | $536M | $646M | $76M | — | $25M |
| FY2023 | 31M | $134M | $35M | $77M | — | $0 |
| FY2022 | 30M | $213M | $35M | $58M | — | $0 |
| FY2021 | 29M | $239M | $10M | $55M | — | — |
| FY2020 | 28M | $335M | $21M | $42M | — | — |
| FY2019 | 25M | $149M | $33M | $26M | — | — |
| FY2018 | — | $78M | $35M | $16M | — | — |
| FY2017 | — | $105M | $45M | $10M | — | — |
| FY2016 | — | $106M | $46M | $2M | — | — |
| FY2015 | — | $25M | $31M | $1M | — | — |
| FY2014 | — | $9M | — | $0.8M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 6, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | IRTC | S&P 500 |
|---|---|---|
| 2019 | −2.0% | +31.5% |
| 2020 | +248.4% | +18.4% |
| 2021 | −50.4% | +28.7% |
| 2022 | −20.4% | −18.1% |
| 2023 | +14.3% | +26.3% |
| 2024 | −15.8% | +25.0% |
| 2025 | +96.8% | +17.9% |
| 2026 to date | −46.9% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Healthcare
- LEGN Legend Down 16%
- VCYT Veracyte Down 54.3%
- IBRX ImmunityBio Down 17.7%
- PACB PacBio Down 11.4%
- IDXX IDEXX Laboratories Up 21.8%
Questions about iRhythm
- Why did iRhythm stock fall on Nov 6, 2026?
- iRhythm raised its 2026 revenue outlook, but only because of an acquisition; without it, the range is about 1% lower than in August. It also delayed the FDA filing for its next heart-monitoring patch to 2027 and said revenue from its Zio AT patch stopped growing. The shares fell about 31%, on a day the S&P 500 rose. Those changes are real, but no source we found explains a fall this large on their own. Read the article →